Market Challenges And Opportunities

Increasing number of organ transplant procedures is expected to drive growth of the global tacrolimus market

The increasing number of organ transplant procedures is expected to drive the market growth over the forecast period. For instance, according to the data published by the U.S. Department of Health & Human Services, in January 2021, a total of 39,034 transplants were performed in the U.S. from both living and deceased donors in 2020.

Increasing research and development activities by pharmaceutical companies are expected to drive the market growth during the forecast period.

Increasing research and development activities by key players for the development and launch of tacrolimus are expected to drive the global tacrolimus market growth over the forecast period. For instance, in June 2018, VIVUS, Inc., a biopharmaceutical company, announced positive preliminary results from a Phase 1 clinical study evaluating the pharmacokinetic (PK) profile of its VI-0106 in healthy volunteers. VIVUS is developing VI-0106, a proprietary soft capsule formulation of tacrolimus for the treatment of pulmonary arterial hypertension (PAH), a degenerative disease that makes it difficult for the heart to pump blood through the lungs to be oxygenated and may ultimately lead to heart failure.

Increasing number of organ transplant procedures (from Growth Drivers section)
Increasing research and development activities by pharmaceutical companies (from Growth Drivers section)

Global Tacrolimus Market: Restraint

The major factors that hinder growth of the global tacrolimus market include side effects and presence of alternative medicine. For instance, tacrolimus may cause serious side effects including decreased urination, pain or burning on urination, pale skin, shortness of breath, fast heartbeat coma (loss of consciousness for a period of time), etc. The most common side effects of tacrolimus include headache, diarrhea, constipation, nausea, and others.